11Nov/21

Veeva Enters Operations Execution Domain in the Cloud

Veeva Vault Quality Briefing Note

Axendia was recently briefed by the Executive team at Veeva Vault Quality, Mike Jovanis, Vice President of Vault Quality, Kent Malmros, Senior Director of Vault Training, Jason Boyd, Senior Director of Vault LIMS, and Gagan Bhatia, Director of Product Marketing.

“We are building the industry cloud for Life Sciences,” affirmed Peter Gassner, President and CEO of Veeva during his keynote at the company’s summit in 2018 (See: Veeva is Building the Life Sciences Cloud with High Speed and Velocity)

Since then, Veeva has made significant investments towards that goal. The company built a cloud native QMS solution, made inroads to provide the right content for the right station on the shop floor with Station Manager (see: Samsung Biologics CIO Shares Vision for Modernizing Manufacturing Quality) as well added new offerings in Learning Management (see: Leading Companies Modernize Quality Management in the Cloud).

During this briefing, Veeva’s Management team provided an update on new product offerings, including the LearnAboutGmp (now Veeva LearnGxP) acquisition, the launch of Vault Validation Management application for paperless validation and the company’s entrance into the Operations Execution Domain with the launch of Vault LIMS.

Continue reading
24Oct/21

3D Printing Capacity Critical in Preparing for a Pandemic

By: Jared N. Matlis, Research Assistant

Preparedness is a skill which is necessary for success in any situation, whether it is a job, schooling, or warfare. So much so that it is immortalized in the Latin phrase Si vis pacem, para bellum, in other words, “if you want peace, prepare for war”. This is a sentiment which the United States knows well, as it has the undisputed best equipped and powerful military in the world.  However, a report from the America Makes <AMCPR> initiative “Assessing the Role of Additive Manufacturing in Support of the U.S. Covid-19 Response”, underwritten by the FDA, depicts how in 2020 the United States was caught unprepared by the invasion of Covid-19.

Continue reading
04Oct/21

Digital Transformation: The Business Imperative for Life-Sciences

By Daniel R. Matlis, President

“Necessity is the mother of invention,” says the ancient proverb.  In my opinion, the corollary is: “disruption is the matriarch of transformation,” especially for the Life-Sciences industries.

The COVID-19 epidemic has been the biggest global disruption in our generation. It represents a watershed moment for transformation throughout our industry.

Disruption is the new normal. This new paradigm is forcing Life-Science companies to re-imagine the way they operate; transforming and accelerating product development, regulatory review, manufacturing, and distribution cycles aimed at improving patient outcomes.

Continue reading
27Sep/21

“Orchestrating” the Sales-to-Manufacturing Process

KBMax Briefing Note

By:  Eric M. Luyer, Industry Research Analyst

Axendia was recently briefed by the executive team at KBMax about their offering to the Bio-Pharma Industry.

KBMax offers innovative and engaging technology in the visual “Configure, Price, Quote” (CPQ) and Visualization market, “orchestrating” the sales-to-manufacturing process in an engineer-to-order environment.  KBMax was acquired by Epicor in May 2021. This acquisition will continue to drive growth for Epicor as they now have the ability to offer KBMax software as a stand-alone system or integrate it into the Epicor ERP suite to generate new, cross and up-sell revenues.

Steve Murphy, CEO of Epicor commented on the acquisition:It’s a perfect time for businesses to reach our customers in new and compelling ways. The integration of KBMax’s technology into our platform will solve that challenge for our customers, enabling them to create an information-rich and immersive online buying experience. The integration of next-gen CPQ tools with our ERP system will enable vital connectivity points to our customers across inventory, costs, pricing, and customer data”.

Continue reading
01Sep/21

FDA Reports on The State of Pharmaceutical Quality

Remote Evaluations, Grading Industry on a Curve and Using AI to Predict Site Inspection Scores

By: Axendia Staff

The FDA issued its latest report on the State of Pharmaceutical Quality.  In the report, the Agency describes Pharmaceutical Quality as the ability of the pharmaceutical manufacturing industry to deliver quality drug products to U.S. patients and consumers. In addition, FDA defines quality drug products as those that are safe and effective and free of contamination and defects.  It is worth noting the absence of the word “compliant” in these definitions.

Hidden among Hand Sanitizer recall data were a number of significant developments on FDA’s regulatory approach.

This Brief represents Axendia’s analysis and insights on FDA’s Report on the State of Pharmaceutical Quality.

Continue reading